Ikuerowo Stephen Odunayo, Ojewuyi Olufemi O, Bioku Muftau Jimoh, Abolarinwa Abimbola Ayodeji, Omisanjo Olufunmilade Akinfolarin
Department of Surgery, Urology Division, Lagos State University College of Medicine, Ikeja, Lagos, Nigeria.
Department of Surgery, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria.
Niger J Surg. 2018 Jan-Jun;24(1):12-15. doi: 10.4103/njs.NJS_25_17.
Mainz II pouch urinary diversion in patients with muscle-invasive bladder cancer is one of the options of continent urinary diversion following radical cystectomy (RC). We aim to report our experience and the outcome of our patients who had this procedure.
Patients who had RC and Mainz II pouch urinary diversion for muscle-invasive bladder cancer in our institution from 2007 to 2016 were evaluated. Variables analyzed included age, gender, stage of the disease, pathological grade and tumor types, complications, and survival status.
There were 11 patients who had Mainz II pouch urinary diversion after RC for bladder cancer over a 10-year period. Four (36%) were male and 7 (64%) were female. The mean age of the patients was 58.6 (range, 52-65) years. The diseases were pT2, pT3, and pT4 in 2 (18%), 7 (64%), and 2 (18%) patients, respectively. Four (36%) had pelvic nodal metastasis. Nine (82%) had a histological diagnosis of transitional cell carcinoma, and two (18%) were squamous cell carcinoma (SCC). Ten (91%) patients had high-grade disease, whereas only 1 (9%) patient had low-grade disease. Short-term morbidities were electrolytes derangement, hypokalemia, and acidosis in 2 (18%) patients and pyelonephritis in 2 (18%) patient. The two patients with invasive SCC had recurrence and death within 12 months of surgery. At present, four of the patients are alive, and seven are dead. Survival till date ranged from 8 to 120 months (mean survival time was 48 months). All patients achieved day and night time continence, and there was no significant long-term morbidity from the method of urinary diversion.
Mainz II pouch urinary diversion is safe and acceptable to most of our patients with good long-term results.
对于肌层浸润性膀胱癌患者,美因茨II式膀胱替代术是根治性膀胱切除术后可控性尿流改道的选择之一。我们旨在报告我们实施该手术的患者的经验及结果。
对2007年至2016年在我院因肌层浸润性膀胱癌接受根治性膀胱切除术及美因茨II式膀胱替代术的患者进行评估。分析的变量包括年龄、性别、疾病分期、病理分级和肿瘤类型、并发症及生存状况。
在10年期间,有11例患者在根治性膀胱切除术后接受了美因茨II式膀胱替代术。4例(36%)为男性,7例(64%)为女性。患者的平均年龄为58.6岁(范围52 - 65岁)。疾病分期为pT2、pT3和pT4的患者分别有2例(18%)、7例(64%)和2例(18%)。4例(36%)有盆腔淋巴结转移。9例(82%)经组织学诊断为移行细胞癌,2例(18%)为鳞状细胞癌(SCC)。10例(91%)患者为高级别疾病,而只有1例(9%)患者为低级别疾病。短期并发症包括2例(18%)患者出现电解质紊乱、低钾血症和酸中毒,2例(18%)患者发生肾盂肾炎。2例浸润性鳞状细胞癌患者在术后12个月内复发并死亡。目前,4例患者存活,7例患者死亡。迄今为止的生存时间为8至120个月(平均生存时间为48个月)。所有患者均实现了日夜自控排尿,且尿流改道方法未导致明显的长期并发症。
美因茨II式膀胱替代术对我们大多数患者来说是安全且可接受的,长期效果良好。